A Wolverine peptide blend is a single lyophilised vial containing BPC-157 and TB-500 together; GLOW adds GHK-Cu, and KLOW adds KPV on top of that. Blends exist because the four component peptides are described in the literature through non-overlapping pathways, so investigators exploring tissue-repair models sometimes want several variables present at once. This guide sets out exactly what is in each vial, the specification of each component, and how to handle a multi-peptide vial in the laboratory.
Key takeaways
- Wolverine = BPC-157 + TB-500. GLOW = BPC-157 + TB-500 + GHK-Cu. KLOW = BPC-157 + TB-500 + GHK-Cu + KPV.
- The blends are co-lyophilised: all components share one cake and one diluent volume, so every component’s concentration is fixed by the same reconstitution decision.
- Each component is described through a different pathway — NO/VEGFR2 signalling, actin sequestration, copper-dependent remodelling and melanocortin-derived anti-inflammatory signalling respectively.
- Component masses are stated on the batch label; the total peptide mass in a vial is the sum, not the figure for any one component.
- GHK-Cu gives a reconstituted blend a characteristic blue tint. That is the copper(II) complex, not contamination.
- Blends are convenient for exploratory work and unsuitable for mechanistic attribution — a result cannot be assigned to one component.
- None of these compounds is an approved medicine. All are supplied strictly for laboratory research.
What are research peptide blends?
A research peptide blend is a vial in which two or more peptides have been combined and freeze-dried together, so the finished product is a single cake containing a stated mass of each component. Reconstituting it with one volume of diluent produces one solution in which every component is present at a concentration set by its own mass and the shared volume.
That is the whole idea, and it carries one important consequence: the component ratio is fixed at manufacture. A researcher can change the absolute concentration of everything by choosing a different diluent volume, but cannot change the proportion of one component relative to another. Any experiment that requires varying that ratio needs single-component vials instead.
Co-lyophilisation also has a quality implication. Because the components are freeze-dried together, the finished cake is a single manufactured article, and the certificate that matters is the one issued against that blend batch — not certificates for the individual peptides that went into it. A blend sold with only single-compound certificates has not been analysed as the product actually supplied.
The names Wolverine, GLOW and KLOW are informal market designations, not chemical names. They describe composition, and the composition is what appears on the label and the certificate of analysis.
Wolverine, GLOW and KLOW composition
All three blends share the same two-peptide core: BPC-157 and TB-500. GLOW layers the copper tripeptide GHK-Cu on top, and KLOW adds the melanocortin-derived tripeptide KPV to the GLOW composition. The progression is strictly additive.
| Blend | Components | Component count | Store category | Indicative price | Product page |
|---|---|---|---|---|---|
| Wolverine | BPC-157 + TB-500 | 2 | Repair & recovery research | from £17 | Wolverine Blend |
| GLOW | BPC-157 + TB-500 + GHK-Cu | 3 | Cosmetic & skin / repair & recovery | from £59 | GLOW Blend |
| KLOW | BPC-157 + TB-500 + GHK-Cu + KPV | 4 | Repair & recovery research | from £65 | KLOW Blend |
The four component peptides
Each component is a well-defined molecule with its own specification. Three of the four are very small — GHK-Cu and KPV are tripeptides, and the TB-500 fragment is a heptapeptide — which is why blend vials can carry several components without a large total mass.
| Component | Sequence / identity | Length | Molecular weight | Described mechanism strand |
|---|---|---|---|---|
| BPC-157 | GEPPPGKPADDAGLV · CAS 137525-51-0 · C62H98N16O22 | 15 residues | ≈ 1419.5 Da | Nitric oxide system; VEGFR2 upregulation; growth-factor receptor expression |
| TB-500 | Ac-LKKTETQ, residues 17–23 of thymosin β4 (Tβ4 CAS 77591-33-4, ≈4963.5 Da) | 7 residues | ≈ 889 Da | G-actin sequestration; cell migration |
| GHK-Cu | Copper(II) complex of Gly-His-Lys (GHK: CAS 49557-75-7, C14H24N6O4, 340.38 Da) | 3 residues | Complex commonly specified at ≈ 402–404 Da | Copper delivery; collagen and matrix gene modulation |
| KPV | Lys-Pro-Val, the C-terminal tripeptide of α-melanocyte-stimulating hormone · C16H30N4O4 | 3 residues | ≈ 342.4 Da | Anti-inflammatory melanocortin fragment; PepT1-mediated uptake reported |
GHK-Cu deserves a note of its own. The tripeptide glycyl-L-histidyl-L-lysine was isolated from human plasma and has a strong affinity for copper(II); the complex is what carries the biological interest. Pickart and Margolina’s 2018 review summarised gene-expression data attributing broad transcriptional effects to GHK, alongside its long-standing association with collagen synthesis in skin fibroblasts.
KPV is the C-terminal tripeptide of α-MSH. Its best-known published characterisation is Dalmasso and colleagues’ 2008 Gastroenterology paper, which reported that KPV is taken up by intestinal epithelial cells through the peptide transporter PepT1 and reduced inflammation in murine colitis models.
Why these four: complementary described pathways
The rationale offered for these particular combinations is that the four components are described in the literature through four different mechanisms, none of which is a variation on another. Signalling environment, cytoskeletal machinery, matrix remodelling and inflammatory tone are genuinely distinct levers.
Reconstituting a multi-peptide vial
A blend vial is reconstituted exactly like a single-component vial — one diluent volume, added slowly, swirled not shaken. The arithmetic is what differs: one volume produces a distinct concentration for every component, and each is calculated from that component’s own stated mass.
- Read the component masses. Take each component’s mass from the batch label or COA before calculating anything.
- Choose one diluent volume. It applies to every component simultaneously — there is no way to dilute one and not the others.
- Equilibrate and add slowly. Bring the vial to room temperature, then run the diluent down the inside wall to avoid foaming.
- Swirl and inspect. Blends containing GHK-Cu will produce a blue-tinted solution; that is the copper complex, not a defect.
- Record each concentration separately. Log mg/mL for every component, not just the total.
- Aliquot. Single-use working volumes reduce contamination risk and repeated warming of the whole vial.
| Stated component mass | Diluent volume | Per-component concentration | Per-component amount in 0.1 mL | Total peptide concentration |
|---|---|---|---|---|
| 5 mg + 5 mg (2 components) | 1 mL | 5.00 mg/mL each | 500 mcg each | 10.00 mg/mL |
| 5 mg + 5 mg (2 components) | 2 mL | 2.50 mg/mL each | 250 mcg each | 5.00 mg/mL |
| 5 mg + 5 mg + 5 mg (3 components) | 2 mL | 2.50 mg/mL each | 250 mcg each | 7.50 mg/mL |
| 5 mg + 5 mg + 5 mg (3 components) | 3 mL | 1.67 mg/mL each | 167 mcg each | 5.00 mg/mL |
| 5 mg × 4 (4 components) | 2 mL | 2.50 mg/mL each | 250 mcg each | 10.00 mg/mL |
| 5 mg × 4 (4 components) | 3 mL | 1.67 mg/mL each | 167 mcg each | 6.67 mg/mL |
Blend or single-component vials?
The decision is about attribution, not convenience. A blend gives one solution with several active components at a fixed ratio; single vials give full control over which components are present and in what proportion, at the cost of more preparation steps.
A blend suits
Exploratory or screening work where the question is whether a combined preparation produces any measurable change; protocols that mirror a published combination; and situations where fewer vials mean fewer handling errors.
Single vials suit
Mechanistic work, dose-ratio experiments, and any study where a result must be attributed to a specific compound. They also allow one component to be omitted as a control — which a fixed blend cannot do.
There is also a stability argument for single vials in longer projects. A blend commits every component to the same storage history, so the shortest-lived component effectively sets the useful life of the whole preparation. Where components differ in sensitivity — a copper complex and a plain tripeptide behave differently in solution — separate vials let each be prepared fresh on its own schedule.
All four component peptides are also stocked individually: BPC-157, TB-500, GHK-Cu and KPV. Building a comparison series from single vials is the only way to run a proper drop-one control design.
COA considerations for blends
A blend certificate has to do more work than a single-compound certificate. It should identify every component by mass spectrometry, report purity for the material, and state the mass of each component in the vial. Four distinct masses — roughly 342, 402, 889 and 1420 Da for a KLOW composition — should be resolvable in the analysis.
Two checks are worth making. First, that the certificate covers the specific blend batch rather than the individual raw peptides used to make it. Second, that the component masses on the certificate match those printed on the vial label, since all the reconstitution arithmetic depends on them.
GenoPept publishes per-batch third-party certificates covering HPLC and MS at /coa-certificates/. The COA reading guide annotates each field, and the purity testing guide explains how the numbers are produced.
Research blends in the GenoPept store
Frequently asked questions
What is in the Wolverine peptide blend?
The Wolverine blend is a single lyophilised vial containing BPC-157 and TB-500 co-freeze-dried together. Both peptides are present in one cake and dissolve into one solution when diluent is added. The mass of each component is stated on the batch label and certificate of analysis, and the ratio is fixed at manufacture.
What is the difference between GLOW and KLOW?
GLOW contains BPC-157, TB-500 and GHK-Cu. KLOW contains those three plus KPV, the C-terminal tripeptide of α-melanocyte-stimulating hormone. The progression is additive: KLOW is GLOW with one further component. Both reconstitute in exactly the same way, into a blue-tinted solution because of the copper complex.
Why does a GLOW or KLOW solution turn blue?
The blue colour comes from GHK-Cu, the copper(II) complex of the tripeptide glycyl-L-histidyl-L-lysine. Copper(II) complexes of this type are characteristically blue in aqueous solution. It is an expected property of the material, not a sign of contamination or degradation. Blends without GHK-Cu, such as Wolverine, reconstitute clear.
How is a multi-peptide vial reconstituted?
Exactly as a single-component vial: equilibrate to room temperature, add diluent slowly down the inside wall, swirl rather than shake, inspect for clarity and aliquot. One diluent volume sets the concentration of every component simultaneously, so each component’s mg/mL is calculated from its own stated mass divided by that shared volume.
Are blends better than buying peptides separately?
Neither is better in general. A blend reduces handling steps and suits exploratory screening. Single vials allow the ratio to be varied and a component to be omitted as a control, which a fixed blend cannot do — so mechanistic work that needs to attribute an effect to one compound calls for single-component vials.
What is KPV?
KPV is the tripeptide Lys-Pro-Val, the C-terminal three residues of α-melanocyte-stimulating hormone, with a molecular weight of about 342.4 Da. Published research reported that it is taken up by intestinal epithelial cells via the PepT1 transporter and reduced inflammation in murine colitis models. It is the fourth component in KLOW.
Do blends need a different COA?
Yes. A blend certificate should identify every component by mass spectrometry and state the mass of each in the vial, referenced to the blend batch rather than to the individual raw peptides. For a KLOW composition, four distinct masses of roughly 342, 402, 889 and 1420 Da should be resolvable.
Do the components have equal molar concentrations in a blend?
No, unless the component masses were deliberately set to achieve that. The molecular weights span roughly 342 Da to 1420 Da, so equal masses give very different molar amounts. At 2.5 mg/mL, KPV sits near 7.3 mM while BPC-157 sits near 1.76 mM — roughly a fourfold difference for the same mass.
References
- Sikiric P, Seiwerth S, Rucman R, et al. Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract. Current Pharmaceutical Design. 2011;17(16):1612–1632. PubMed
- Seiwerth S, Milavic M, Vukojevic J, et al. Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology. 2021;12:627533. doi:10.3389/fphar.2021.627533
- Cushman DM, et al. Regeneration or risk? A narrative review of BPC-157 for musculoskeletal healing. Current Reviews in Musculoskeletal Medicine. 2025;18(12):611–619. doi:10.1007/s12178-025-09990-7
- Malinda KM, et al. Thymosin beta4 accelerates wound healing. Journal of Investigative Dermatology. 1999;113(3):364–368. PubMed
- Goldstein AL, Hannappel E, Kleinman HK. Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine. 2005. PubMed
- Esposito S, Deventer K, et al. Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential. Drug Testing and Analysis. 2012. doi:10.1002/dta.1402
- Pickart L, Margolina A. Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data. International Journal of Molecular Sciences. 2018;19(7):1987. doi:10.3390/ijms19071987
- Dalmasso G, et al. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166–178. PubMed
Research-grade peptide blends, batch-verified
GenoPept supplies the Wolverine, GLOW and KLOW blends as co-lyophilised vials with per-batch third-party certificates of analysis covering HPLC purity and mass-spectrometry identity, dispatched from the UK, strictly for laboratory research.